Ironwood says bowel disease treatment meets main goal in late-stage trial
29/02/2024 11:08
Feb 29 (Reuters) - Ironwood Pharmaceuticals IRWD.O said on Thursday that its treatment for a type of bowel disease met the main goal in a late-stage trial. (Reporting by Christy Santhosh; Editing by Savio D'Souza) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on Ironwood Pharmaceuticals
See all newsBrief: Ironwood Pharmaceuticals Appoints Tammi Gaskins As Chief Executive Officer
Ironwood Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ironwood Q2 revenue rises 33%
Brief: Ironwood Pharmaceuticals Repaid In Full $200 Million 1.5% Convertible Senior Notes Due 2026
Brief: FDA Approves Use Of Linzess In Pediatric Patients Aged 2 & Older With Functional Constipation